AlphAIAlphAI — Financial news for AI agents
MarketBeatMAR 174 min read$DCGO

DocGo (NASDAQ:DCGO) Price Target Cut to $2.50 by Analysts at Stifel Nicolaus

Stifel Nicolaus has lowered its price target for DocGo (NASDAQ:DCGO) to $2.50 from $4.00, while maintaining a "buy" rating, indicating a potential upside of 218%. Despite a Q4 revenue beat and raised 2026 revenue guidance of $290M–$310M, the company faces significant execution risk due to a large EPS miss, year-over-year revenue decline, and weak margins, with the stock currently trading around $0.79. DocGo is exploring strategic alternatives to push towards profitability.

Original reporting
MarketBeat · MarketBeat
Published Mar 17, 2026, 2:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 17, 2026, 3:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
DocGo (NASDAQ:DCGO) Price Target Cut to $2.50 by Analysts at Stifel Nicolaus — source image
Source · MarketBeat
Decision brief

The 30-second read

$DCGOBearishLow
01

Why it matters

However, the analyst's significant price target cut and concerns over EPS and margins suggest underlying challenges that could impact stock performance.

02

Market read

The news is highly relevant to current and potential investors in DocGo, especially those trading on short to medium-term horizons.

03

What to watch

Potential for a short squeeze if the stock remains undervalued and trading volume increases; upcoming catalysts such as strategic alternatives announcement could alter the outlook.

Timing: short-term

Background

DocGo reported a Q4 revenue beat and raised revenue guidance for 2026, indicating operational strength.

Company-level read

Ticker impact

$DCGOBearishMedium confidence
Context

The news directly pertains to DocGo (NASDAQ:DCGO), highlighting a significant analyst price target revision and company performance factors.

Expected impact

Potential short-term decline or sideways movement; long-term outlook remains uncertain due to execution risks.

Evidence & confidence

The conflicting signals—positive revenue guidance versus negative analyst outlook and execution risks—create uncertainty. Technical levels and current valuation suggest limited upside, but the low stock price leaves room for volatility.

Market effects

Sector

The healthcare and life sciences sectors may experience slight negative sentiment due to company-specific issues.

Regional

Limited regional impact; the news is specific to a US-listed company.

Global

Minimal; the company's size and market cap suggest limited influence on global markets.

Counterpoint

What could challenge this read

The lowered price target may already be priced in, and the company's strategic initiatives could lead to future upside if execution improves.

Key entities

  • Financial Analyst Firm
    Stifel Nicolaus

    The firm that revised the price target for DocGo.

  • Company
    DocGo

    The subject of the analyst review, operating in healthcare services.

Read at source← All news

Related articles

AUG 20
Med

DocGo Inc. Q2 2026 Earnings Call Summary

DocGo Inc. reported Q2 2026 earnings, highlighting a 19% year-over-year revenue increase in core business lines, despite a $6.3M adjusted EBITDA loss. The company announced its largest acquisition, Hicuity Health, aiming to integrate hospital and home care. Management expects to achieve positive adjusted EBITDA by year-end 2026, with revenue guidance narrowed to $305M-$310M. Cost synergies and efficiency programs are expected to drive future growth.

yahoo.com2 min
AUG 19
$DCGOMed

DocGo Shares Tumble After Earnings Miss and Wider Loss Forecast

DocGo (DCGO) shares fell 12.7% pre-market Tuesday after Q2 2026 earnings missed estimates, with a $0.16 loss per share vs. expected $0.10. Revenue was $73.4M, down 8.7% YoY, and the company widened its full-year adjusted EBITDA loss forecast to $17M-$22M. The decline followed the end of migrant-related contracts, though core revenue grew 19%. The stock trades near its 52-week low of $0.451.

yahoo.com2 min
AUG 19
$DCGOMed

DocGo Q2 Earnings Call Highlights

DocGo reported record service volumes in Q2, with year-over-year growth across all core businesses. The company acquired Hicuity, assuming $52M in debt and issuing 2% equity. DocGo's revenue rose to $52M in medical transportation but fell in mobile health due to migrant-related work decline. Adjusted EBITDA loss narrowed to $6.3M. The company updated its full-year outlook, expecting a wider EBITDA loss of $17M-$22M. DocGo has $48.1M in cash and expects positive adjusted EBITDA run rate by year-e

yahoo.com3 min
AUG 19
$DCGOMed

DocGo Inc (DCGO) (Q2 2026) Earnings Call Highlights: Record Volumes and Strategic

DocGo Inc (DCGO) reported Q2 2026 revenue of $73.4M, down from $80.4M YoY, and widened its adjusted EBITDA loss guidance to $17M-$22M. Gross margins declined due to lower margins in the Mobile Health segment and higher fuel costs. The company's cash position decreased to $48.1M. The Hicuity acquisition faces regulatory and customer approval hurdles. Organic revenue grew approximately 5% YoY. The company aims to achieve adjusted EBITDA breakeven by the end of 2026 through revenue growth, improved

yahoo.com7 min
AUG 18
$DCGOHighAI 9/10

Why is DocGo stock tumbling today?

DocGo (DCGO) shares fell 12.7% pre-open to $0.62 after its Q2 2026 adjusted loss was $0.16 per share versus $0.10 consensus. Revenue was $73.4M, below $75.4M forecast and down 8.7% YoY, tied to wind-down of migrant contracts. It widened FY2026 adjusted EBITDA loss to $17M-$22M and agreed to acquire Hicuity Health (~$65M trailing revenue).

investing.com4 min